0.52
price up icon3.05%   0.0154
after-market Handel nachbörslich: .52
loading
Schlusskurs vom Vortag:
$0.5046
Offen:
$0.51
24-Stunden-Volumen:
83,670
Relative Volume:
2.04
Marktkapitalisierung:
$17.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-563.30K
KGV:
-2.6052
EPS:
-0.1996
Netto-Cashflow:
$-22.23M
1W Leistung:
+2.97%
1M Leistung:
-10.81%
6M Leistung:
-44.68%
1J Leistung:
-69.49%
1-Tages-Spanne:
Value
$0.50
$0.52
1-Wochen-Bereich:
Value
$0.47
$0.6095
52-Wochen-Spanne:
Value
$0.47
$2.37

Promis Neurosciences Inc Stock (PMN) Company Profile

Name
Firmenname
Promis Neurosciences Inc
Name
Telefon
416-847-6898
Name
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
PMN's Discussions on Twitter

Vergleichen Sie PMN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PMN
Promis Neurosciences Inc
0.52 16.51M 0 -563.30K -22.23M -0.1996
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten

pulisher
May 18, 2025

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying - MSN

May 18, 2025
pulisher
May 14, 2025

ProMIS Neurosciences Reports Q1 2025 Progress and Financials - TipRanks

May 14, 2025
pulisher
May 13, 2025

ProMIS Neurosciences (NASDAQ:PMN) Now Covered by Maxim Group - Defense World

May 13, 2025
pulisher
May 13, 2025

ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 12, 2025

ProMIS Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences (PMN): Maxim Group Initiates Coverage with Buy Rating | PMN Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Maxim Group Initiates Coverage of ProMIS Neurosciences (PMN) with Buy Recommendation - Nasdaq

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences Announces First Quarter 2025 Financial Resu - GuruFocus

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences (PMN) Advances Alzheimer's Clinical Program - GuruFocus

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

ProMIS Neurosciences Announces First Quarter 2025 Financial Results - GlobeNewswire

May 12, 2025
pulisher
Apr 26, 2025

Multiple System Atrophy Treatment Algorithm, Clinical Trials - openPR.com

Apr 26, 2025
pulisher
Apr 17, 2025

Parkinson’s vaccine selectively targets pathogenic αSyn - BioWorld MedTech

Apr 17, 2025
pulisher
Apr 04, 2025

ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India

Apr 04, 2025
pulisher
Apr 04, 2025

Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN

Apr 04, 2025
pulisher
Apr 02, 2025

ProMIS Neurosciences’ (PMN) Buy Rating Reaffirmed at Guggenheim - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

ProMIS Neurosciences Reports 2024 Financial Turnaround - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

ProMIS Neurosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

PROMIS NEUROSCIENCES Earnings Results: $PMN Reports Quarterly Earnings - Nasdaq

Mar 31, 2025
pulisher
Mar 31, 2025

ProMIS Neurosciences Inc. (PMN) reports earnings - Quartz

Mar 31, 2025
pulisher
Mar 31, 2025

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Form 424B5 ProMIS Neurosciences - StreetInsider

Mar 31, 2025
pulisher
Mar 31, 2025

ProMIS Neurosciences Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 28, 2025

ProMIS Neurosciences Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView

Mar 28, 2025
pulisher
Mar 25, 2025

ProMIS to present neurodegenerative disease research By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

New Diagnostics And Treatments Transform Neurodegenerative Disease Care - Evrim Ağacı

Mar 24, 2025
pulisher
Mar 24, 2025

ProMIS to present neurodegenerative disease research - Investing.com India

Mar 24, 2025
pulisher
Mar 24, 2025

ProMIS Neurosciences Showcases Preclinical Data on - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference - Yahoo Finance

Mar 24, 2025
pulisher
Mar 23, 2025

ProMIS Neurosciences (PMN) Expected to Announce Quarterly Earnings on Monday - Defense World

Mar 23, 2025
pulisher
Mar 20, 2025

Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Multiple System Atrophy Market to Reach New Heights in Growth - openPR

Mar 20, 2025
pulisher
Mar 13, 2025

ProMIS to present vaccine data at neurology meeting By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

ProMIS to present vaccine data at neurology meeting - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - The Manila Times

Mar 13, 2025
pulisher
Mar 13, 2025

ProMIS Neurosciences to Present Preclinical Data on Computational Vaccine Development for Neurodegenerative Diseases at AAN Annual Meeting - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

ProMIS Neurosciences Showcases Preclinical Data on Platform - GlobeNewswire

Mar 13, 2025
pulisher
Mar 12, 2025

PROMIS NEUROSCIENCES Earnings Preview: Recent $PMN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 12, 2025
pulisher
Mar 11, 2025

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewswire

Mar 11, 2025
pulisher
Mar 01, 2025

ProMIS Neurosciences’ (PMN) “Buy” Rating Reiterated at Guggenheim - Defense World

Mar 01, 2025
pulisher
Feb 25, 2025

ProMIS Neurosciences begins Alzheimer’s trial dosing - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times

Feb 25, 2025
pulisher
Feb 25, 2025

ProMIS Neurosciences begins Alzheimer’s trial dosing By Investing.com - Investing.com South Africa

Feb 25, 2025

Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Kapitalisierung:     |  Volumen (24h):